Amylin's Bydureon endures rejection; finally embraced by FDA
This article was originally published in Scrip
As if it had 1980s disco diva Gloria Gaynor singing it to the finish line, Amylin's Type II diabetes drug Bydureon (exenatide extended-release for injectable suspension) – twice rejected by the US FDA and recently separated from longtime partner Lilly – indeed survived, and finally won US approval on 27 January.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.